Tagged with tech

Saudi Arabia Saudi Arabia has long represented an alluring marketplace for the global MedTech industry. Not only does the Kingdom constitute the largest spender on healthcare across the Middle East and North Africa region, but its medical device sector has been experiencing consistent compound annual growth rates of over six percent and…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…

Switzerland Catherine Pickering, CEO of iOnctura, explains how her agile Swiss biotech is pioneering precision small-molecule therapies to overcome tumour resistance, with a focus on lead asset – roginolisib and a pipeline built on novel scientific mechanisms. She discusses the company’s evolution from seed funding through Series B and the role…

USA As the search for effective Alzheimer’s treatments continues to evolve, Annovis Bio is taking a distinct approach with buntanetap, a novel oral candidate designed to intervene more broadly in disease progression. In this interview, Chief Business Officer Mark White discusses the company’s clinical learnings, operational discipline, and the realities of…

Hong Kong Few biotech companies emerge with both scientific depth and a clear sense of direction. Innorna, founded by Dr Linxian Li after years spent refining RNA delivery systems in academic settings, is one of them. What began as a technical platform matured through a pandemic-era proof of concept and now moves…

Hong Kong At the Centre for Oncology and Immunology, a flagship of Hong Kong’s Health@InnoHK initiative, science converges across disciplines and continents. Under the leadership of Professor Tak Wah Mak, the Centre is advancing a new understanding of how immune responses are shaped, not only by tumours, but by the nervous system…

Switzerland Founded in 2017 by a group of biotech veterans with deep expertise in antibody engineering, CDR-Life has evolved into a platform-driven company advancing next-generation T-cell engagers for oncology and autoimmune disease. With assets progressing through clinical trials and a strategic partnership already in place, CEO Christian Leisner discusses how the…

Switzerland From its roots as a family-run ophthalmology business to its bold reinvention as a precision oncology biotech, CIS Biopharma is charting a distinctive course through the rapidly evolving life sciences landscape. Leading this transformation, CEO Christoph Schäfer shares the strategic rationale behind the company’s evolution, offering insight into how scientific…

Saudi Arabia As Saudi Arabia reshapes its healthcare sector, Japanese-headquartered medtech player Terumo is deepening its presence, moving beyond market expansion to integration, innovation, and local manufacturing. Elias El Zoughbi, Country Manager for Terumo in Saudi Arabia, is at the helm of this transformation. Navigating a landscape where global expertise meets national…

Switzerland Nicolas Durand, CEO of Fondation Campus Biotech Geneva, shares insights into the foundation’s unique role as a catalyst for neuroscience and digital health innovation in Switzerland. In this interview, Durand discusses the foundation’s collaborative model, the importance of building critical mass in a specialised domain, and how Fondation Campus Biotech…

Puerto Rico We’re not just building facilities—we’re building the future of medicine, where innovation is inclusive, access is equitable, and every breakthrough brings us closer to a healthier world. Biopharmaceutical innovation is advancing rapidly, yet inefficiencies in development and manufacturing continue to slow progress. OcyonBio, under the leadership of CEO Robert Salcedo,…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…